sevirumab: Clinical Trials

6 completed. 4 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	4	Completed 4
Phase 1	3	Completed 3
Phase 3	1	Completed 1

Follow sevirumab: new trials by email Literature Review of sevirumab trials Research Report on sevirumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT) MSL-109, Placebo - HIV Infections, Cytomegalovirus Retinitis	Phase 2 / Phase 3	Completed	Johns Hopkins Bloomberg School of Public Health	209	1995-09-01	2015-11-17
Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease SDZ MSL-109 - Cytomegalovirus Infections	Phase 1 / Phase 2	Completed	National Center for Research Resources (NCRR)		1995-02-01	2005-06-24
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria Sevirumab - Cytomegalovirus Infections, HIV Infections	Phase 1	Completed	Sandoz			2005-06-24
A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) Sevirumab - Cytomegalovirus Retinitis, HIV Infections	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	300		2012-10-25
Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS Sevirumab, Foscarnet sodium, Ganciclovir - Cytomegalovirus Retinitis, HIV Infections	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	167		2021-11-01
A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis Sevirumab - Cytomegalovirus Retinitis, HIV Infections	Phase 1	Completed	Sandoz			2005-06-24

Conditions studied

HIV Infections (5)  ·  Cytomegalovirus Retinitis (4)  ·  AIDS-Related Opportunistic Infections (3)  ·  Acquired Immunodeficiency Syndrome (3)  ·  Cytomegalovirus Infections (3)  ·  Multiple Acyl Coenzyme A Dehydrogenase Deficiency (2)  ·  Communicable Diseases (1)  ·  Herpesviridae Infections (1)  ·  Immune System Diseases (1)  ·  Infant, Newborn, Diseases (1)  ·  Rare Diseases (1)  ·  Retinitis (1)  ·  Virus Diseases (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Sandoz (2)  ·  Johns Hopkins Bloomberg School of Public Health (1)  ·  National Center for Research Resources (NCRR) (1)

Countries

United States (4)

Top investigators

Borucki M (1)  ·  Gnann J (1)  ·  Hirsch MS (1)  ·  Pollard RB (1)  ·  Richard J. Whitley (1)

Results publications

PMID 11919489, PMID 12232843, PMID 12559647, PMID 15498605, PMID 31042791, PMID 9400786